US 11,873,478 B2
Method for reducing immunogenicity of RNA
Katalin Kariko, Rydal, PA (US); and Ugur Sahin, Mainz (DE)
Assigned to BioNTech SE, Mainz (DE)
Filed by BioNTech SE, Mainz (DE)
Filed on Sep. 4, 2020, as Appl. No. 17/012,599.
Application 17/012,599 is a division of application No. 15/755,309, granted, now 10,808,242, previously published as PCT/EP2016/070012, filed on Aug. 24, 2016.
Application 15/755,309 is a continuation in part of application No. PCT/EP2015/069760, filed on Aug. 28, 2015.
Prior Publication US 2020/0399629 A1, Dec. 24, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/10 (2006.01); C12N 15/67 (2006.01); C12P 19/34 (2006.01); C12N 15/88 (2006.01); C07K 14/505 (2006.01)
CPC C12N 15/102 (2013.01) [C07K 14/505 (2013.01); C12N 15/10 (2013.01); C12N 15/67 (2013.01); C12N 15/88 (2013.01); C12P 19/34 (2013.01)] 20 Claims
 
1. A modified RNA comprising an adenosine-rich first nucleotide sequence having an adenosine content of more than 25% and encoding at least one peptide or protein; wherein the peptide or protein encoded by the first nucleotide sequence is also encoded by a second nucleotide sequence of a second, naturally occurring RNA; and the first nucleotide sequence has a higher A content and a lower U content compared to the second nucleotide sequence; wherein the first nucleotide sequence comprises nucleotide residues selected from adenosine (A), guanosine (G), and cytidine (C) at positions corresponding to uracil (U) nucleotide residue positions in the second nucleotide sequence; thereby rendering the modified RNA at least 5% less immunogenic than the second RNA.